DK2712610T3 - Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse - Google Patents

Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse

Info

Publication number
DK2712610T3
DK2712610T3 DK13179876.1T DK13179876T DK2712610T3 DK 2712610 T3 DK2712610 T3 DK 2712610T3 DK 13179876 T DK13179876 T DK 13179876T DK 2712610 T3 DK2712610 T3 DK 2712610T3
Authority
DK
Denmark
Prior art keywords
preparation
methods
cyclic lipid
implants
intraocular use
Prior art date
Application number
DK13179876.1T
Other languages
English (en)
Inventor
Lon T Spada
James N Chang
Michelle Luu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2712610T3 publication Critical patent/DK2712610T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
DK13179876.1T 2006-12-19 2007-12-12 Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse DK2712610T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/612,928 US8846073B2 (en) 2006-12-19 2006-12-19 Low temperature processes for making cyclic lipid implants for intraocular use
EP07855073.8A EP2124879B1 (en) 2006-12-19 2007-12-12 Processes for making cyclic lipid implants for intraocular use

Publications (1)

Publication Number Publication Date
DK2712610T3 true DK2712610T3 (da) 2018-01-29

Family

ID=39467138

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13179876.1T DK2712610T3 (da) 2006-12-19 2007-12-12 Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse
DK07855073.8T DK2124879T3 (da) 2006-12-19 2007-12-12 Fremgangsmåder til fremstilling af cykliske lipidimplantater til intraokulær anvendelse
DK17198020.4T DK3308769T3 (da) 2006-12-19 2007-12-12 Fremgangsmåder til fremstilling af cykliske lipidimplantater til intraokulær anvendelse

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK07855073.8T DK2124879T3 (da) 2006-12-19 2007-12-12 Fremgangsmåder til fremstilling af cykliske lipidimplantater til intraokulær anvendelse
DK17198020.4T DK3308769T3 (da) 2006-12-19 2007-12-12 Fremgangsmåder til fremstilling af cykliske lipidimplantater til intraokulær anvendelse

Country Status (11)

Country Link
US (5) US8846073B2 (da)
EP (3) EP3308769B1 (da)
JP (2) JP5484911B2 (da)
AU (1) AU2007337139B2 (da)
CA (1) CA2673294C (da)
DK (3) DK2712610T3 (da)
ES (3) ES2851748T3 (da)
HK (1) HK1253728A1 (da)
HU (3) HUE053530T2 (da)
PL (3) PL2124879T3 (da)
WO (1) WO2008079674A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
CA2667890C (en) * 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP4108216A1 (en) 2009-06-03 2022-12-28 Forsight Vision5, Inc. Anterior segment drug delivery
DK3085358T3 (da) * 2010-01-22 2018-02-05 Allergan Inc Intrakamerale implantater med depotpræparat
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
CA2804035A1 (en) * 2010-06-30 2012-01-05 Evonik Degussa Corporation Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2012149278A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Sustained release latanoprost implant
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
US20140271772A1 (en) * 2013-03-15 2014-09-18 Barry J. Margulies Biodegradable subcutaneous implants and methods of making
CN109568672B (zh) * 2013-03-15 2022-06-24 阿勒根公司 含有前列腺胺的眼内植入物
EP2978406A1 (en) * 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
US9492316B2 (en) 2013-10-31 2016-11-15 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
RU2728195C2 (ru) 2014-02-26 2020-07-28 Аллерган, Инк. Устройство доставки внутриглазного имплантата и способы его использования
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
EP3518897B1 (en) 2016-09-30 2022-02-09 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
SG11202000497VA (en) * 2017-07-25 2020-02-27 PK Med SAS Process for preparing a drug delivery composition
KR102531760B1 (ko) * 2017-11-13 2023-05-10 한동희 다기능성 생체적합실
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
WO2021053167A1 (de) * 2019-09-19 2021-03-25 Amw Gmbh Extrudierte depotform mit kontrollierter wirkstofffreisetzung
AU2021215929A1 (en) 2020-02-06 2022-08-04 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
WO2023107478A1 (en) * 2021-12-06 2023-06-15 Ocular Therapeutix, Inc. Extruded ocular inserts or implants and methods thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5882327A (en) * 1997-04-17 1999-03-16 Jacob; Jean T. Long-term glaucoma drainage implant
CA2300154C (en) 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
RU2355385C2 (ru) 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20080038317A1 (en) 2004-09-10 2008-02-14 Chin-Ming Chang Therapeutic Lacrimal Canalicular Inserts And Related Methods
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8293261B2 (en) 2005-01-28 2012-10-23 Terumo Kabushiki Kaisha Intravascular implant
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
ES2834964T3 (es) * 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
US9492316B2 (en) * 2013-10-31 2016-11-15 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof

Also Published As

Publication number Publication date
PL3308769T3 (pl) 2021-07-26
DK3308769T3 (da) 2021-02-01
JP5484911B2 (ja) 2014-05-07
US20200038326A1 (en) 2020-02-06
HK1253728A1 (zh) 2019-06-28
US20210322318A1 (en) 2021-10-21
EP2124879A2 (en) 2009-12-02
AU2007337139A1 (en) 2008-07-03
EP2712610B1 (en) 2017-10-25
US8846073B2 (en) 2014-09-30
WO2008079674A3 (en) 2008-10-23
AU2007337139B2 (en) 2013-05-09
JP2014088448A (ja) 2014-05-15
US20160022581A1 (en) 2016-01-28
DK2124879T3 (da) 2016-09-05
WO2008079674A2 (en) 2008-07-03
US20080145403A1 (en) 2008-06-19
HUE053530T2 (hu) 2021-07-28
HUE030404T2 (en) 2017-05-29
CA2673294C (en) 2015-07-21
JP5826872B2 (ja) 2015-12-02
EP2712610A1 (en) 2014-04-02
ES2657143T3 (es) 2018-03-01
US9149428B2 (en) 2015-10-06
US10441543B2 (en) 2019-10-15
PL2124879T3 (pl) 2017-01-31
PL2712610T3 (pl) 2018-05-30
US20140364494A1 (en) 2014-12-11
ES2588187T3 (es) 2016-10-31
CA2673294A1 (en) 2008-07-03
EP2124879B1 (en) 2016-05-25
JP2010513555A (ja) 2010-04-30
ES2851748T3 (es) 2021-09-08
EP3308769B1 (en) 2020-10-28
HUE037939T2 (hu) 2018-09-28
EP3308769A1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
DK2712610T3 (da) Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse
WO2007147010A3 (en) Implantable medical devices and methods for making the same
WO2009121565A3 (en) Expansible biocompatible coats comprising a biologically active substance
WO2008034013A3 (en) Medical devices and methods of making the same
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
DK1868600T3 (da) Spirocyklisk cyclohexanderivat til behandling af stofafhængighed
BRPI0718927A2 (pt) Método de imunização contra os quatro sorotipos da dengue.
WO2010147957A3 (en) Dithiol compounds, derivatives, and uses therefor
DE602007000478D1 (de) Akkomodatives Intraokularlinsensystem
BR112013002365A2 (pt) moldes de dispositivo oftálmico e métodos relacionados
BRPI0914387A2 (pt) sistema de tratamento abdominal, método de tratamento de uma cavidade abdominal aberta, e, método de fabricação de um sistema para tratamento de uma cavidade abdominal de um paciente
BRPI0906750B8 (pt) material polimérico biocompatível poroso e métodos
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
WO2008091835A3 (en) Implantable medical endoprostheses
WO2007058842A3 (en) Medical device with a grooved surface
BRPI0920137A2 (pt) implante ocular
WO2008157733A3 (en) Fibrin gel for controlled release of pdgf and uses thereof
CR11731A (es) Composiciones y procedimientos para su preparación y uso
WO2014143754A3 (en) Prostamide-containing intraocular implant
CL2007003671A1 (es) Metodo para la preparacion de derivados del acido 2-amino-5-cianobenzoico, utiles como intermediarios para la preparacion de las correspondientes diamidas cianoantranilicas.
DK2148667T3 (da) Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
WO2009111635A3 (en) Dithiol compounds, derivatives, and uses therefor
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood